Integrative analysis of drug response and clinical outcome in acute myeloid leukemia by Bottomly, Daniel, Long, Nicola, Schultz, Anna Reister, Kurtz, Stephen E., Tognon, Cristina E., Johnson, Kara, Abel, Melissa, Agarwal, Anupriya, Avaylon, Sammantha, Benton, Erik, Blucher, Aurora, Borate, Uma, Braun, Theodore P., Brown, Jordana, Bryant, Jade, Burke, Russell, Carlos, Amy, Chang, Bill H., Cho, Hyun Jun, Christy, Stephen, Coblentz, Cody, Cohen, Aaron M., d’Almeida, Amanda, Cook, Rachel, Danilov, Alexey, Dao, Kim-Hien T., Degnin, Michie, Dibb, James, Eide, Christopher A., English, Isabel, Hagler, Stuart, Harrelson, Heath, Henson, Rachel, Ho, Hibery, Joshi, Sunil K., Junio, Brian, Kaempf, Andy, Kosaka, Yoko, Laderas, Ted, Lawhead, Matt, Lee, Hyunjung, Leonard, Jessica T., Lin, Chenwei, Lind, Evan F., Liu, Selina Qiuying, Lo, Pierrette, Loriaux, Marc M., Luty, Samuel, Maxson, Julia E., Macey, Tara, Martinez, Jacqueline, Minnier, Jessica, Monteblanco, Andrea, Mori, Motomi, Morrow, Quinlan, Nelson, Dylan, Ramsdill, Justin, Rofelty, Angela, Rogers, Alexandra, Romine, Kyle A., Ryabinin, Peter, Saultz, Jennifer N., Sampson, David A., Savage, Samantha L., Schuff, Robert, Searles, Robert, Smith, Rebecca L., Spurgeon, Stephen E., Sweeney, Tyler, Swords, Ronan T., Thapa, Aashis, Thiel-Klare, Karina, Traer, Elie, Wagner, Jake, Wilmot, Beth, Wolf, Joelle, Wu, Guanming, Yates, Amy, Zhang, Haijiao, Cogle, Christopher R., Collins, Robert H., Deininger, Michael W., Hourigan, Christopher S., Jordan, Craig T., Lin, Tara L., Martinez, Micaela E., Pallapati, Rachel R., Pollyea, Daniel A., Pomicter, Anthony D., Watts, Justin M., Weir, Scott J., Druker, Brian J., McWeeney, Shannon K., Tyner, Jeffrey W.

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance by O'Hare, Thomas, Shakespeare, William C., Zhu, Xiaotian, Eide, Christopher A., Rivera, Victor M., Wang, Frank, Adrian, Lauren T., Zhou, Tianjun, Huang, Wei-Sheng, Xu, Qihong, Metcalf, Chester A., Tyner, Jeffrey W., Loriaux, Marc M., Corbin, Amie S., Wardwell, Scott, Ning, Yaoyu, Keats, Jeffrey A., Wang, Yihan, Sundaramoorthi, Raji, Thomas, Mathew, Zhou, Dong, Snodgrass, Joseph, Commodore, Lois, Sawyer, Tomi K., Dalgarno, David C., Deininger, Michael W.N., Druker, Brian J., Clackson, Tim

Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia by Bicocca, Vincent T., Chang, Bill H., Masouleh, Behzad Kharabi, Muschen, Markus, Loriaux, Marc M., Druker, Brian J., Tyner, Jeffrey W.

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms by Tyner, Jeffrey W., Bumm, Thomas G., Deininger, Jutta, Wood, Lisa, Aichberger, Karl J., Loriaux, Marc M., Druker, Brian J., Burns, Christopher J., Fantino, Emmanuelle, Deininger, Michael W.

Aurora A kinase as a target for therapy in TCF3-HLF rearranged acute lymphoblastic leukemia by Leonard, Jessica, Wolf, Joelle SJ, Degnin, Michelle, Eide, Christopher A., LaTocha, Dorian, Lenz, Kyle, Wilmot, Beth, Mullighan, Charles G., Loh, Mignon, Hunger, Stephen P, Druker, Brian J, Loriaux, Marc M, Tyner, Jeffrey W, Chang, Bill H

SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia by Paiva, Cody, Rowland, Taylor A., Sreekantham, Bhargava, Godbersen, Claire, Best, Scott R., Kaur, Prabhjot, Loriaux, Marc M., Spurgeon, Stephen E.F., Danilova, Olga V., Danilov, Alexey V.

Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples by Edwards V, David K., Sweeney, David Tyler, Ho, Hibery, Eide, Christopher A., Rofelty, Angela, Agarwal, Anupriya, Liu, Selina Qiuying, Danilov, Alexey V., Lee, Patrice, Chantry, David, McWeeney, Shannon K., Druker, Brian J., Tyner, Jeffrey W., Spurgeon, Stephen E., Loriaux, Marc M.

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients by Tyner, Jeffrey W., Erickson, Heidi, Deininger, Michael W.N., Willis, Stephanie G., Eide, Christopher A., Levine, Ross L., Heinrich, Michael C., Gattermann, Norbert, Gilliland, D. Gary, Druker, Brian J., Loriaux, Marc M.

TSLP Signaling Network Revealed by SILAC-Based Phosphoproteomics by Zhong, Jun, Kim, Min-Sik, Chaerkady, Raghothama, Wu, Xinyan, Huang, Tai-Chung, Getnet, Derese, Mitchell, Christopher J., Palapetta, Shyam M., Sharma, Jyoti, O'Meally, Robert N., Cole, Robert N., Yoda, Akinori, Moritz, Albrecht, Loriaux, Marc M., Rush, John, Weinstock, David M., Tyner, Jeffrey W., Pandey, Akhilesh

RNAi screen for rapid therapeutic target identification in leukemia patients by Tyner, Jeffrey W, Deininger, Michael W, Loriaux, Marc M, Chang, Bill H, Gotlib, Jason R, Willis, Stephanie G, Erickson, Heidi, Kovacsovics, Tibor, O'Hare, Thomas, Heinrich, Michael C, Druker, Brian J

Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression by Beer, Philip A., Knapp, DavidJ.H.F., Miller, Paul H., Kannan, Nagarajan, Sloma, Ivan, Heel, Kathy, Babovic, Sonja, Bulaeva, Elizabeth, Rabu, Gabrielle, Terry, Jefferson, Druker, Brian J., Loriaux, Marc M., Loeb, Keith R., Radich, Jerald P., Erber, Wendy N., Eaves, Connie J.

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability by Lannutti, Brian J., Meadows, Sarah A., Herman, Sarah E.M., Kashishian, Adam, Steiner, Bart, Johnson, Amy J., Byrd, John C., Tyner, Jeffrey W., Loriaux, Marc M., Deininger, Mike, Druker, Brian J., Puri, Kamal D., Ulrich, Roger G., Giese, Neill A.

Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia by Lamble, Adam J., Kosaka, Yoko, Laderas, Ted, Maffit, Allie, Kaempf, Andy, Brady, Lauren K., Wang, Weiwei, Long, Nicola, Saultz, Jennifer N., Mori, Motomi, Soong, David, LeFave, Clare V., Huang, Fei, Adams, Homer, Loriaux, Marc M., Tognon, Cristina E., Lo, Pierrette, Tyner, Jeffrey W., Fan, Guang, McWeeney, Shannon K., Druker, Brian J., Lind, Evan F.

TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms by Fleischman, Angela G., Aichberger, Karl J., Luty, Samuel B., Bumm, Thomas G., Petersen, Curtis L., Doratotaj, Shirin, Vasudevan, Kavin B., LaTocha, Dorian H., Yang, Fei, Press, Richard D., Loriaux, Marc M., Pahl, Heike L., Silver, Richard T., Agarwal, Anupriya, O'Hare, Thomas, Druker, Brian J., Bagby, Grover C., Deininger, Michael W.

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition by Fleischman, Angela G., Maxson, Julia E., Luty, Samuel B., Agarwal, Anupriya, Royer, Lacey R., Abel, Melissa L., MacManiman, Jason D., Loriaux, Marc M., Druker, Brian J., Tyner, Jeffrey W.

Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine by Bottomly, Daniel, Ryabinin, Peter A, Tyner, Jeffrey W, Chang, Bill H, Loriaux, Marc M, Druker, Brian J, McWeeney, Shannon K, Wilmot, Beth

CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation by Gordon, Max J., Tardi, Paul, Loriaux, Marc M., Spurgeon, Stephen E., Traer, Elie, Kovacsovics, Tibor, Mayer, Lawrence D., Tyner, Jeffrey W.

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib by McWeeney, Shannon K., Pemberton, Lucy C., Loriaux, Marc M., Vartanian, Kristina, Willis, Stephanie G., Yochum, Gregory, Wilmot, Beth, Turpaz, Yaron, Pillai, Raji, Druker, Brian J., Snead, Jennifer L., MacPartlin, Mary, O'Brien, Stephen G., Melo, Junia V., Lange, Thoralf, Harrington, Christina A., Deininger, Michael W.N.

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor by Burke, Russell T, Meadows, Sarah, Loriaux, Marc M, Currie, Kevin S., Mitchell, Scott A., Maciejewski, Patricia, Clarke, Astrid S., Dipaolo, Julie A., Druker, Brian J., Lannutti, Brian J., Spurgeon, Stephen E.

Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma by Siegel, Matthew B., Liu, Selina Qiuying, Davare, Monika A., Spurgeon, Stephen E., Loriaux, Marc M., Druker, Brian J., Scott, Emma C., Tyner, Jeffrey W.